ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024. "Gilead delivered another exceptionally ...
Updated recommendations were issued by the IAS-USA regarding the use of ART for treatment and prevention of HIV in adult populations.
Data from the Phase III PURPOSE 1 and PURPOSE 2 trials demonstrated lenacapavir's superior HIV prevention efficacy compared to Gilead’s once-daily oral Truvada (emtricitabine + tenofovir ...
The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various factors.
Truvada contains emtricitabine and tenofovir disoproxil fumarate. The latter is an older form of tenofovir that has been associated with possible kidney and bone side effects, though it is generally ...
Strengths of Truvada are listed in mg of emtricitabine/tenofovir disoproxil fumarate. Below are the dosages of Descovy and Truvada for treating or helping prevent HIV in children. Strengths of ...
Compared with the entecavir group, patients in the tenofovir group, including tenofovir disoproxil fumarate and tenofovir alafenamide fumarate showed a significant increase in estimated glomerular ...
Taken as a preventive measure against acquiring HIV, and meant to lower acquisition risk, Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead), Descovy (emtricitabine/tenofovir ...
The TN group was further subdivided into TMF (n = 63) and tenofovir disoproxil fumarate (TDF, n = 60) subgroups. In the TE group, patients transitioned from prior antiviral therapies (entecavir or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results